Rhythm Capital's stock price has fluctuated significantly over the past year, with a high of $12.50 and a low of $8.50.
The company's market capitalization has increased by 25% in the past quarter, indicating growing investor interest.
Rhythm Capital's stock price has outperformed the broader market, with a return on investment of 15% compared to the S&P 500's 5% return.
Investors should carefully consider the company's financials and growth prospects before making a decision.
Worth a look: S B I Card Share Price
Rithm Capital Performance
Rithm Capital Corp. has seen a significant increase in revenue, with a growth rate of 139% year-over-year (YOY).
The company's profit margin is a respectable 24.6%, indicating that it's able to maintain a healthy margin on its sales.
However, the earnings growth YOY has taken a hit, with a decline of 50.6% - this could be a cause for concern for investors.
Let's take a closer look at Rithm Capital's performance metrics:
Market Comparison and Analysis
Rithm Capital's performance has been impressive, with a 1-year return of +13.52% and a 5-year return of +7.74%.
In comparison, the S&P has seen a 1-year return of +22.93% and a 5-year return of +83.67%.
Rithm Capital's 5-year annualized return of +1.50% is lower than the S&P's +12.93%.
However, Rithm Capital has still managed to deliver a +202% return since its IPO, which is a significant achievement.
Here's a table comparing the performance of Rithm Capital and the S&P over the past 1, 5, and since IPO periods:
Rithm Capital has also surpassed Q1 expectations with solid growth, outperforming analysts' forecasts.
Ownership and Estimates
Let's break down the ownership and estimates of Rhythm Capital's stock price.
Rhythm Capital is a publicly traded company, listed on the Euronext Paris stock exchange. It has a market capitalization of approximately €1.5 billion.
The company's ownership structure is quite diverse, with a significant portion of shares held by institutional investors. These investors include The Vanguard Group, Inc. and BlackRock, Inc.
Rhythm Capital's estimates for future growth and revenue are based on its current business strategy and market trends.
A unique perspective: Ventas Inc Stock Price
7 Analyst Ratings
Rhythm Pharmaceuticals has received a lot of attention from analysts, with 7 analysts providing their ratings and price targets over the past few months.
Analysts are generally optimistic about Rhythm Pharmaceuticals, with 4 of the 7 analysts maintaining a "Buy" rating.
Here are the details of each analyst's rating:
It's worth noting that the analysts' ratings and price targets vary widely, with some predicting a 30% upside and others a 39% upside.
4.06% Less Ownership
Let's take a closer look at the numbers behind ownership and estimates.
Funds ownership actually decreased by 4.06% in Q3 compared to Q2.
This drop is significant, given that funds ownership had been steadily increasing.
In Q2, funds ownership reached 114.85%, but by Q3, it had fallen to 110.78%.
Rhythm Pharmaceuticals USD Estimates
Rhythm Pharmaceuticals is expected to have a significant increase in revenue, with estimates ranging from 182 USD in 2025 to 970 USD in 2028.
The company's net profit is also expected to grow, from -155 USD in 2025 to 438 USD in 2028.
Rhythm Pharmaceuticals' earnings per share (EPS) is expected to turn positive in 2027, with estimates ranging from -2.46 USD in 2025 to 6.28 USD in 2028.
Here's a breakdown of the company's revenue and net profit estimates for the next few years:
The company's research and development expenses are expected to increase, from 163 USD in 2025 to 193 USD in 2028.
Rhythm Pharmaceuticals' cash flow from operations is expected to turn positive in 2027, with estimates ranging from -40 USD in 2025 to 614 USD in 2028.
The company's shareholder's equity is expected to increase, from 438 USD in 2025 to 452 USD in 2026.
Rhythm Pharmaceuticals' net debt is expected to decrease, from -272 USD in 2025 to -389 USD in 2026.
The company's average revenue estimate for 2026 is 39 USD, with 8 analysts providing estimates.
The average net profit estimate for 2026 is -49 USD, with 8 analysts providing estimates.
Rhythm Pharmaceuticals' annual general meeting is expected to be held in June 2024, with actual EPS of -3.200 USD.
Consider reading: Cloudflare Stock Quote
The company's Q4 2023 earnings release is expected to be released on February 22, 2024, with actual EPS of -0.700 USD.
The company's Q3 2023 earnings release is expected to be released on November 7, 2023, with actual EPS of -0.760 USD.
Rhythm Pharmaceuticals' Q2 2023 earnings release is expected to be released on August 1, 2023, with actual EPS of -0.820 USD.
The company's Q1 2023 earnings release is expected to be released on May 2, 2023, with actual EPS of -0.920 USD.
The company's Q4 2022 earnings release is expected to be released on March 1, 2023, with actual EPS of -0.750 USD.
The company's Q3 2022 earnings release is expected to be released on November 8, 2022, with actual EPS of -0.790 USD.
Rhythm Pharmaceuticals' Q2 2022 earnings release is expected to be released on August 2, 2022, with actual EPS of -0.890 USD.
The company's Q1 2022 earnings release is expected to be released on May 3, 2022, with actual EPS of -1.050 USD.
The company's Q4 2021 earnings release is expected to be released on March 1, 2022, with actual EPS of -0.850 USD.
Consider reading: Lseg Earnings
Frequently Asked Questions
What is the future price of RITM stock?
According to analyst forecasts, the predicted future price of RITM stock is around $12.78, indicating a potential 17.03% increase from its current price of $10.92.
How often does Rhythm Capital pay dividends?
Rithm Capital pays dividends quarterly, every three months. The exact payment schedule is based on the company's ex-dividend date, which is typically announced in advance.
Featured Images: pexels.com
